LifeMD Signs Direct GLP-1 Fulfillment Deals With Eli Lilly and Novo Nordisk

LifeMD signed direct fulfillment arrangements with Eli Lilly and Novo Nordisk to dispense branded GLP-1 weight-loss medications through its affiliated pharmacy, the company said on its third quarter 2026 earnings call on November 12, 2026. The Motley Fool covered the call.

LifeMD's Direct GLP-1 Pharmacy Arrangements

LifeMD said the arrangements with Eli Lilly and Novo Nordisk let it integrate self-pay GLP-1 medications directly into its pharmacy operations. The company handles prescribing, fulfillment and clinical support on a single telehealth platform, which it says removes third-party friction and captures higher gross profit dollars per subscriber.

"In the last 30 days, we completed arrangements with both Eli Lilly and Novo Nordisk that enable us to integrate self-pay GLP-1 medications directly into our pharmacy operations, further expanding access to these products by removing friction from the patient experience," said Justin Schreiber, LifeMD's chairman and chief executive officer.

LifeMD also launched an enterprise collaboration with AT&T giving 100 million wireless and fiber customers and 110,000 employees access to complimentary memberships. Schreiber said the channel gives LifeMD access to patients at a small fraction of the acquisition cost it typically sees through paid media.

Management lowered the introductory monthly price for its weight management program from $75 to $39. Schreiber said customer acquisition cost declined 40% from its peak in June, and the share of new patients selecting multi-month plans increased from approximately 25% to approximately 85%.

LifeMD's Patient Base and Lilly History

According to akta.pro company records, LifeMD serves approximately 350,000 patients across its 50-state virtual care platform, and its website states "Join Over 745K Patients." The same records show more than 322,000 active subscribers across GLP-1 and women's health programs as of early March 2026, and a partnership in April 2026 with Eli Lilly to offer the FDA-approved oral GLP-1 Foundayo (orforglipron) through the LifeMD platform.

Earlier LifeMD GLP-1 and AT&T Steps

In November 2026, LifeMD announced an arrangement with Eli Lilly to dispense and ship Lilly's self-pay GLP-1 medicines, including Zepbound and Foundayo, to eligible patients across the U.S., with the program cash-pay and not billed to insurance, Stock Titan reported. In September 2026, AT&T began waiving the $19 monthly LifeMD membership fee, a $228 annual value, for eligible wireless and fiber customers through its &More program, with 29 million customers in 11 states receiving it first and nationwide expansion in January 2027, Stock Titan reported.

LifeMD's 2027 Outlook

LifeMD said it expects fixed overhead to remain flat even as patient volume expands in 2027. AT&T's waiver of the LifeMD membership fee expands nationwide in January 2027.